News
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback